Sign in or create an account to add this stock to your watchlist.
About Silence Therapeutics (LON:SLN)
Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SLN
CUSIPN/A
Phone+44-20-34576900
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-34,475.00%
Return on Equity-21.42%
Return on Assets-20.54%
Miscellaneous
EmployeesN/A
Outstanding Shares69,990,000
Silence Therapeutics (LON:SLN) Frequently Asked Questions
What is Silence Therapeutics' stock symbol?
Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."
How were Silence Therapeutics' earnings last quarter?
Silence Therapeutics (LON:SLN) announced its quarterly earnings data on Tuesday, March, 6th. The company reported ($2.30) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter. Silence Therapeutics had a negative net margin of 34,475.00% and a negative return on equity of 21.42%. View Silence Therapeutics' Earnings History.
What price target have analysts set for SLN?
1 brokers have issued 12-month price objectives for Silence Therapeutics' shares. Their forecasts range from GBX 277 to GBX 277. On average, they anticipate Silence Therapeutics' stock price to reach GBX 277 in the next year. View Analyst Ratings for Silence Therapeutics.
Who are some of Silence Therapeutics' key competitors?
Some companies that are related to Silence Therapeutics include Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix BioTherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Gr (MVF), Horizon Discovery (HZD), IMV (IMV), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF) and Arix Bioscience (ARIX).
Who are Silence Therapeutics' key executives?
Silence Therapeutics' management team includes the folowing people:
- Mr. Ali Mortazavi, Chief Exec. Officer and Director (Age 47)
- Mr. David J. Ellam, Chief Financial Officer, Sec. and Director (Age 54)
- Dr. Torsten Hoffmann, Chief Operating Officer (Age 51)
- Dr. Dmitry Samarsky Ph.D., Chief Scientific Officer (Age 51)
- Dr. Mark Cameron, Head of Chemistry
Has Silence Therapeutics been receiving favorable news coverage?
Headlines about SLN stock have been trending positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Silence Therapeutics earned a news impact score of 0.40 on Accern's scale. They also gave press coverage about the company an impact score of 47.09 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Silence Therapeutics?
Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Silence Therapeutics' stock price today?
One share of SLN stock can currently be purchased for approximately GBX 152.25.
How big of a company is Silence Therapeutics?
Silence Therapeutics has a market capitalization of £136.14 million.
How can I contact Silence Therapeutics?
Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.
MarketBeat Community Rating for Silence Therapeutics (SLN)
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Silence Therapeutics (LON:SLN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Silence Therapeutics in the last 12 months. Their average twelve-month price target is GBX 277The high price target for SLN is GBX 277 and the low price target for SLN is GBX 277. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 277 | GBX 277 | GBX 275 | GBX 249 |
Silence Therapeutics (LON:SLN) Consensus Price Target History
Silence Therapeutics (LON:SLN) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 4/3/2018 | Peel Hunt | Reiterated Rating | Buy | GBX 277 |  |
| 1/9/2017 | Canaccord Genuity | Reiterated Rating | Buy | GBX 249 | |
(Data available from 5/23/2016 forward)
Silence Therapeutics (LON:SLN) Earnings History and Estimates Chart
Silence Therapeutics (LON SLN) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/6/2018 | Y 2017 | | GBX (2.30) | | GBX 2 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Silence Therapeutics (LON:SLN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Silence Therapeutics (LON SLN) Insider Trading and Institutional Ownership History
Silence Therapeutics (LON SLN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/2/2017 | Alistair Gray | Insider | Buy | 3,848 | GBX 130 | £5,002.40 | | |
| 7/31/2017 | Andy Richards | Insider | Buy | 7,000 | GBX 147 | £10,290 | | |
| 4/18/2016 | Mortazavi,Ali | Insider | Buy | 160,000 | GBX 125 | £200,000 | | |
(Data available from 1/1/2013 forward)
Silence Therapeutics (LON SLN) News Headlines
| Source: |
|
Silence Therapeutics (LON:SLN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Silence Therapeutics (LON SLN) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
